Gabriel Sciences

Gabriel Sciences is a clinical-stage biotechnology company dedicated to developing innovative therapies for neurological and neuropsychiatric disorders, with a primary focus on epilepsy. The company's lead candidate, GS-101, is a proprietary sublingual formulation of a GABA-A receptor positive allosteric modulator designed for the treatment of acute repetitive seizures (ARS). By providing a rapid-acting and non-invasive delivery method, Gabriel Sciences aims to improve the management of seizure clusters compared to traditional rectal or nasal administrations. The company leverages its expertise in GABAergic signaling to address significant unmet needs in the central nervous system space. Headquartered in San Francisco, Gabriel Sciences is advancing its clinical programs to provide better outcomes for patients living with refractory epilepsy.